Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2016

Hames Megan L, Chen Heidi, Iams Wade, Aston Jonathan, Lovly Christine M, Horn Leora

Abstract excerpt

OBJECTIVES: KRAS mutations are the most commonly found mutations in patients with non-small cell lung cancer (NSCLC) adenocarcinoma histology. The clinical implications of KRAS mutations in patients with advanced NSCLC are not well defined. We sought to determine if there is a correlation between KRAS mutation status, response to cytotoxic chemotherapy, and survival in patients with metastatic or recurrent NSCLC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26775593
DOI: 10.1016/j.lungcan.2015.11.004
PMCID: PMC4874190

Genes

KRAS
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.PMID 26775593Read ↗

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.Semantic proximity Read ↗

Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Semantic proximity Read ↗

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.Semantic proximity Read ↗

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?Semantic proximity Read ↗

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.Semantic proximity Read ↗

Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.Semantic proximity Read ↗

Potential Clinical Significance of a Plasma-Based <i>KRAS</i> Mutation Analysis in Patients with Advanced Non–Small Cell Lung CancerSemantic proximity Read ↗

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.Semantic proximity Read ↗

KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.Semantic proximity Read ↗

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Semantic proximity Read ↗

KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.